<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182765</url>
  </required_header>
  <id_info>
    <org_study_id>1100.1244</org_study_id>
    <nct_id>NCT02182765</nct_id>
  </id_info>
  <brief_title>Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults</brief_title>
  <official_title>An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE®), Abacavir and Amprenavir in HIV-1 Infected NNRTI Naive Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the effects of 28 days of nevirapine treatment on the steady-state&#xD;
      pharmacokinetics of amprenavir and of abacavir and to further evaluate the pharmacokinetics&#xD;
      of nevirapine in combination with amprenavir and abacavir compared to historical controls&#xD;
      treated with nevirapine but without amprenavir or abacavir. In addition safety/tolerance of&#xD;
      nevirapine, amprenavir and abacavir was to be assessed based on adverse events and clinical&#xD;
      laboratory data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 1999</start_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (area under plasma concentration time curve) of amprenavir in the absence and presence of nevirapine</measure>
    <time_frame>Day 14, day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum observed concentration of the analyte in plasma) of amprenavir in the absence and presence of nevirapine</measure>
    <time_frame>Day 14, day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (area under plasma concentration time curve) of abacavir in the absence and presence of nevirapine</measure>
    <time_frame>Day 14, day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum observed concentration of the analyte in plasma) of abacavir in the absence and presence of nevirapine</measure>
    <time_frame>Day 14, day 43</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HIV-1 Ribonucleic Acid (RNA)</measure>
    <time_frame>Baseline, day 14, 21, 28, 35, 43 (Part I), up to 168 days (Part II)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Lymphocytes Expressing CD4+ cell count</measure>
    <time_frame>Baseline, day 14, 21, 28, 35, 43 (Part I), up to 168 days (Part II)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieved RNA levels below limit of quantification (BLoQ) (responders)</measure>
    <time_frame>up to 43 days (Part I), up to 168 days (Part II)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 240 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>Baseline, day 14, 28, 43 (Part I), up to 168 days (Part II)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Nevirapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I: Study days 15-43&#xD;
Part II: Study day 44 to end of trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amprenavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part I: Study days 0 to 43&#xD;
Part II: Study day 44 to end of trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abacavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part I: Study days 0 to 43&#xD;
Part II Study day 44 to end of trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <arm_group_label>Nevirapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amprenavir</intervention_name>
    <arm_group_label>Amprenavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir</intervention_name>
    <arm_group_label>Abacavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients between the ages of 18 and 65 years, inclusive;&#xD;
&#xD;
          -  Plasma HIV-1 RNA &gt;= 5000 copies/mL, documenting HIV-1 infection&#xD;
&#xD;
          -  CD4+ cell count &gt;= 100 cells/mm³&#xD;
&#xD;
          -  Patients who met the following laboratory parameter:&#xD;
&#xD;
               -  Lymphocyte count &gt;= 1000 cells/mm³&#xD;
&#xD;
               -  Hemoglobin &gt;= 9.0 g/dl (men and women)&#xD;
&#xD;
               -  Platelet count &gt;= 75000 cells/mm3&#xD;
&#xD;
               -  Alkaline Phosphatase &lt;= 3.0 times the upper limit of normal&#xD;
&#xD;
               -  Serum Glutamic-Oxaloacetic Transaminase (SGOT) and Serum Glutamic-Pyruvic&#xD;
                  Transaminase (SGPT) &lt;= 3.0 times the upper limit of normal&#xD;
&#xD;
               -  Total bilirubin &lt;= 1.5 times the upper limit of normal&#xD;
&#xD;
               -  Creatinine &lt;= 2mg/dL&#xD;
&#xD;
          -  Female patients of reproductive potential had to be willing to use a reliable method&#xD;
             of double-barrier contraception (such as diaphragm with spermicidal cream or jelly, or&#xD;
             condoms with spermicidal foam)&#xD;
&#xD;
          -  Patients who were informed of and willing and able to comply with the investigational&#xD;
             nature of the study and had signed a written consent in accordance with institutional&#xD;
             and federal guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who were pregnant or breast-feeding&#xD;
&#xD;
          -  Female patients who intended to change their double-barrier contraception method&#xD;
             within 28 days prior to Study Day 0 and throughout the trial&#xD;
&#xD;
          -  Patients who in the opinion of the investigator required treatment with a prohibited&#xD;
             medication during the study including the potentially toxic substrates such as&#xD;
             terfenadine, bepridil, astemizole, cisapride, triazolam, midazolam and&#xD;
             ergotamine/dihydroergotamine containing regimes&#xD;
&#xD;
          -  Patients taking known inhibitors or inducers of Cytochrome P450 metabolic enzymes&#xD;
             including macrolide antibiotics (erythromycin, clarithromycin, azithromycin) azole&#xD;
             antifungals (fluconazole, itraconazole) and phenytoin within 28 days prior or Study&#xD;
             day 0 and throughout the trial&#xD;
&#xD;
          -  Patients receiving immunomodulatory agents&#xD;
&#xD;
          -  Ketoconazole, rifabutin and rifampin were excluded during screening and throughout the&#xD;
             trial&#xD;
&#xD;
          -  Patients with previous exposure to anti-retroviral, such as delavirdine, loviride,&#xD;
             efavirenz, nevirapine, abacavir, saquinavir, ritonavir, indinavir, nelfinavir,&#xD;
             amprenavir, zidovudine, Lamivudine (3TC), Stavudine (d4T), Didanosine (ddI) and&#xD;
             Zalcitabine (ddC)&#xD;
&#xD;
          -  Patients receiving any investigational drug or systemic corticosteroids within 30 days&#xD;
             of the first dose of study medication and system corticosteroids initially as well as&#xD;
             throughout the study and any antineoplastic agent of radiotherapy other than local&#xD;
             skin radiotherapy treatment within 12 weeks before starting study medication&#xD;
&#xD;
          -  Patients with malabsorption, severe chronic diarrhea or patients unable to maintain&#xD;
             adequate oral intake&#xD;
&#xD;
          -  Patients currently abusing alcohol or substance abusing; patients on methadone&#xD;
             substitution programs might be considered for inclusion in the trial&#xD;
&#xD;
          -  Patients undergoing treatment for an active infection&#xD;
&#xD;
          -  Patients with hepatic insufficiency due to cirrhosis&#xD;
&#xD;
          -  Patients with renal insufficiency&#xD;
&#xD;
          -  Patients who were heavy smokers (e.g. &gt; 20 cigarettes per day)&#xD;
&#xD;
          -  Patients whose reliability was deemed to put them at risk for non-compliance with the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1100/1100.1244_U02-3077.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 3, 2014</study_first_submitted>
  <study_first_submitted_qc>July 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Amprenavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

